Brief: Aelis Farma Receives Positive Recommendation To Continue AEF0117 Phase 2B Clinical Study

Aelis Farma SA

05/07/2023 06:05

July 5 (Reuters) - Aelis Farma SA  AELIS.PA :
    * AELIS FARMA RECEIVES A POSITIVE RECOMMENDATION FROM THE
DSMB TO
CONTINUE, WITH NO MODIFICATION TO THE PROTOCOL, THE PHASE 2B
CLINICAL STUDY WITH AEF0117 IN CANNABIS ADDICTION
    * COMPOUND'S FAVORABLE SAFETY AND TOLERABILITY PROFILE
ALLOWS TO
CONFIDENTLY CONTINUE PHASE 2B OF AEF0117, WITH FIRST RESULTS
EXPECTED IN MID-2024
    * ENROLLMENT IN STUDY IS CONTINUING AT A SUSTAINED PACE,
ENABLING
FIRST RESULTS TO BE ANTICIPATED IN MID-2024, AS EXPECTED
    * FOLLOWING MEETING, COMMITTEE OBSERVED NO SERIOUS ADVERSE
EVENTS
OR SIGNIFICANT EVENTS ASSOCIATED WITH TREATMENT AND RECOMMENDED
THAT STUDY BE CONTINUED WITHOUT ANY MODIFICATIONS TO PROTOCOL
    * PHASE 2B STUDY WITH AEF0117, CURRENTLY BEING UNDERTAKEN IN
11
CLINICAL CENTERS IN UNITED STATES, AIMS TO DEMONSTRATE EFFICACY
OF AEF0117 IN TREATING CANNABIS USE DISORDER, MODERN MEDICAL
DEFINITION OF CANNABIS ADDICTION

Source text for Eikon:  ID:nBw2NhC1Na 
Further company coverage:  AELIS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))